$42.90

+0.00 (+0.00%)

OTC · Healthcare · Medical - Pharmaceuticals · Tech Score Sell · Power 40 · $14.9B mcap · 181M float · 0.0000% daily turnover · Short 86% of daily vol

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions Dark Pool Short Interest

Income Trends

Revenue

$28.2B +8.2% ▲

5Y CAGR: +13.0%

Gross Profit

$12.3B -39.3% ▼

5Y CAGR: +0.4%

Operating Income

$8.0B +42.7% ▲

5Y CAGR: +10.8%

Net Income

$477M -87.7% ▼

5Y CAGR: -31.9%

EPS (Diluted)

$1.38 -87.7% ▼

5Y CAGR: -33.2%

EBITDA

$10.9B +17.5% ▲

5Y CAGR: +10.3%

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$15.5B	$18.8B	$22.1B	$26.0B	$28.2B
YoY Growth	+1.8%	+21.0%	+17.7%	+17.6%	+8.2%
Cost of Revenue	$3.5B	$4.8B	$5.0B	$5.8B	$15.9B
Gross Profit	$12.0B	$14.0B	$17.1B	$20.2B	$12.3B
Gross Margin	77.6%	74.6%	77.4%	77.8%	43.6%
R&D Expenses	$2.0B	$2.4B	$2.8B	$3.5B	$3.2B
SG&A Expenses	$6.3B	$7.8B	$10.2B	$11.1B	$11.1B
Operating Expenses	$8.3B	$10.2B	$13.1B	$14.6B	$4.3B
Operating Income	$3.7B	$3.8B	$4.1B	$5.6B	$8.0B
Operating Margin	24.0%	20.3%	18.4%	21.6%	28.5%
Interest Expense	$0	$458M	$1.1B	$1.2B	$829M
Income Before Tax	$3.3B	$3.3B	$3.0B	$4.4B	$34M
Tax Expense	$616M	$683M	$546M	$528M	-$441M
Net Income	$2.7B	$2.6B	$2.4B	$3.9B	$477M
Net Margin	17.3%	14.0%	10.9%	14.9%	1.7%
EPS (Diluted)	$8.62	$8.44	$7.39	$11.24	$1.38
EBITDA	$5.7B	$6.1B	$7.2B	$9.3B	$10.9B
Shares Outstanding	311M	312M	326M	346M	348M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$6.9B	$7.4B	$6.5B	$6.2B	$7.7B	$7.8B	$7.2B	$7.8B
Cost of Revenue	$1.3B	$1.6B	$1.6B	$1.4B	$9.0B	$2.2B	$1.7B	$1.8B
Gross Profit	$5.6B	$5.8B	$4.9B	$4.7B	-$1.3B	$5.6B	$5.4B	$6.0B
Gross Margin	80.7%	78.5%	75.4%	76.9%	-16.3%	71.5%	75.7%	76.7%
R&D Expenses	$845M	$981M	$834M	$851M	$749M	$877M	$948M	$1.1B
SG&A Expenses	$1.8B	$3.2B	$1.8B	$2.0B	-$4.8B	$3.0B	$1.9B	$1.7B
Operating Expenses	$3.5B	$4.2B	$3.5B	$3.7B	-$4.1B	$1.1B	$3.6B	$3.9B
Operating Income	$2.0B	$1.7B	$1.4B	$1.0B	$2.8B	$2.4B	$1.9B	$2.1B
Operating Margin	29.6%	22.4%	21.0%	16.4%	36.4%	30.2%	26.0%	26.4%
Interest Expense	$326M	$225M	$262M	$216M	$167M	$185M	$18M	$0
Income Before Tax	$1.7B	$1.4B	$1.1B	$794M	-$4.0B	$2.2B	$1.7B	$1.4B
Tax Expense	$248M	$47M	$221M	$160M	-$1.1B	$309M	$363M	$315M
Net Income	$1.5B	$1.4B	$875M	$636M	-$2.9B	$1.9B	$1.3B	$1.1B
Net Margin	21.2%	18.8%	13.5%	10.3%	-37.2%	23.8%	18.3%	14.0%
EPS (Diluted)	$4.22	$4.03	$2.52	$1.83	$-8.34	$5.33	$3.77	$3.14
EBITDA	$3.0B	$2.6B	$2.3B	$1.9B	$3.6B	$3.1B	$2.6B	$3.3B
Shares Outstanding	347M	347M	347M	347M	345M	349M	349M	350M

BIOVF OTC

Income Trends

Profit Margins

Year-over-Year Growth

Sign in to InsiderStreet